Form 4: MBX Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Carl L. Gordon, a director of MBX Biosciences, acquired stock options for 15,963 shares at an exercise price of $16 on September 12, 2024.
Summary
- On September 12, 2024, Carl L. Gordon, a director of MBX Biosciences, acquired stock options for 15,963 shares.
- The exercise price of these options is $16.
- 25% of the shares underlying the option vest on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued service.
- Gordon is obligated to transfer any securities issued under these options, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will ensure the benefits are provided to OrbiMed Private Investments VII, LP.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedule suggests a long-term commitment.
Future Outlook
The vesting schedule indicates a long-term incentive plan for the director, aligning his interests with the company's performance over the next several years.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The vesting schedule encourages long-term commitment and performance.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Vesting schedules, such as the one described, are typical to ensure long-term alignment with company goals.
- Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.
Related Party Transactions
- Carl L. Gordon is obligated to transfer any securities issued under these options, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will ensure the benefits are provided to OrbiMed Private Investments VII, LP.
Stakeholder Impact
- The stock option grant incentivizes the director to work towards increasing shareholder value.
- The arrangement with OrbiMed suggests a close relationship between MBX Biosciences and OrbiMed Private Investments VII, LP.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of transaction: Carl L. Gordon acquired stock options for 15,963 shares. |
| 09/12/2025 | 25% of the shares underlying the option vest and become exercisable. |
| 09/11/2034 | Expiration date of the stock options. |
| 09/13/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.